High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability.

[1]  E. Trabetti,et al.  807 C/T Polymorphism of the glycoprotein Ia gene and pharmacogenetic modulation of platelet response to dual antiplatelet treatment , 2004, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[2]  C. Macaya,et al.  Is a 300 mg clopidogrel loading dose sufficient to inhibit platelet function early after coronary stenting? A platelet function profile study. , 2004, The Journal of invasive cardiology.

[3]  Deepak L. Bhatt,et al.  Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. , 2004, The American journal of cardiology.

[4]  J. Heikkilä,et al.  Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions. , 2004, European heart journal.

[5]  P. Watkins,et al.  Contribution of Hepatic Cytochrome P450 3A4 Metabolic Activity to the Phenomenon of Clopidogrel Resistance , 2004, Circulation.

[6]  A. Kastrati,et al.  A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. , 2004, The New England journal of medicine.

[7]  E. Trabetti,et al.  PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation , 2004, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[8]  Zhongyan Li,et al.  Effects of Statins on Platelet Inhibition by a High Loading Dose of Clopidogrel , 2003, Circulation.

[9]  A. Kastrati,et al.  Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. , 2003, JAMA.

[10]  MartineAiach,et al.  Adenosine Diphosphate–Induced Platelet Aggregation Is Associated With P2Y12 Gene Sequence Variations in Healthy Subjects , 2003 .

[11]  S. Steinhubl,et al.  Lack of Adverse Clopidogrel–Atorvastatin Clinical Interaction From Secondary Analysis of a Randomized, Placebo-Controlled Clopidogrel Trial , 2003, Circulation.

[12]  P. Fontana,et al.  Adenosine Diphosphate–Induced Platelet Aggregation Is Associated With P2Y12 Gene Sequence Variations in Healthy Subjects , 2003, Circulation.

[13]  Kevin P. Bliden,et al.  Clopidogrel for Coronary Stenting Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity , 2003, Circulation.

[14]  M. Gawaz,et al.  Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement , 2003, Thrombosis and Haemostasis.

[15]  E. Topol,et al.  A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. , 2003, Journal of the American College of Cardiology.

[16]  P. Gurbel,et al.  Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. , 2003, American heart journal.

[17]  Paul B. Watkins,et al.  Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation: A New Drug–Drug Interaction , 2003, Circulation.

[18]  Eric J Topol,et al.  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[19]  A. Kastrati,et al.  Clopidogrel therapy in patients undergoing coronary stenting: Value of a high‐loading‐dose regimen , 2002, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[20]  D. Pfeiffer,et al.  Effect of 300- and 450-mg clopidogrel loading doses on membrane and soluble P-selectin in patients undergoing coronary stent implantation. , 2002, American heart journal.

[21]  J. Willerson,et al.  Monitoring platelet function in glycoprotein IIB/IIIA inhibitor therapy. , 2001, Circulation.

[22]  P. Teirstein,et al.  Point-of-Care Measured Platelet Inhibition Correlates With a Reduced Risk of an Adverse Cardiac Event After Percutaneous Coronary Intervention: Results of the GOLD (AU-Assessing Ultegra) Multicenter Study , 2001, Circulation.

[23]  M. Seyfarth,et al.  Comparison of effects of clopidogrel versus ticlopidine on platelet function in patients undergoing coronary stent placement. , 2001, The American journal of cardiology.

[24]  M. Seyfarth,et al.  Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement , 2001, Heart.

[25]  V. Fuster,et al.  Acute Antithrombotic Effect of a Front-Loaded Regimen of Clopidogrel in Patients With Atherosclerosis on Aspirin , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[26]  C. Thalamas,et al.  Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. , 2000, Circulation.

[27]  Inger Anne Hagberg, Torstein Lyberg.  Blood platelet activation evaluated by flow cytometry: optimised methods for clinical studies , 2000, Platelets.

[28]  J. Moses,et al.  Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. , 1999, Circulation.

[29]  J. Hauert,et al.  Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. , 1999, Seminars in thrombosis and hemostasis.

[30]  C J Knight,et al.  Increased platelet responsiveness following coronary stenting. Heparin as a possible aetiological factor in stent thrombosis. , 1998, European heart journal.

[31]  M. Dennis.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee , 1996 .

[32]  David Schultz,et al.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996, The Lancet.

[33]  D. Clement.  A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .

[34]  Z. Ruggeri,et al.  New insights into the mechanisms of platelet adhesion and aggregation. , 1994, Seminars in hematology.